Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Key Takeaways

• CTA approval adds France, Romania sites to ELIMINATE‑B trial
• Expands trial to six continents, boosting patient enrollment
• PBGENE‑HBV targets cccDNA, the root cause of chronic hepatitis B
• FDA granted Fast Track status, highlighting regulatory support
• Screening to begin Q2 2026, aiming for broader data set

Pulse Analysis

Chronic hepatitis B remains a global health challenge, affecting an estimated 296 million people and accounting for over 800,000 deaths annually from liver cirrhosis and cancer. Current antivirals suppress viral replication but rarely achieve a functional cure because the covalently closed circular DNA (cccDNA) reservoir persists in liver cells. Eliminating cccDNA is widely regarded as the "holy grail" of HBV therapy, and Precision BioSciences’ ARCUS® platform offers a one‑time, in‑vivo gene‑editing approach that directly excises this viral template, potentially delivering a durable cure where existing treatments fall short.

Precision’s PBGENE‑HBV program is the first clinical‑stage candidate designed to eradicate cccDNA while also inactivating integrated HBV DNA fragments. The therapy’s Fast Track designation by the FDA underscores regulatory enthusiasm for novel curative strategies. By securing CTA approval in France and Romania, the company not only broadens geographic diversity but also taps into robust European clinical‑research infrastructure, which can accelerate patient recruitment and generate data reflective of varied genotypes. The new sites complement a network that already spans three continents, positioning ELIMINATE‑B as one of the most globally distributed HBV trials to date.

If the trial demonstrates sustained loss of HBV DNA—a regulatory‑acceptable endpoint—the implications for the biotech sector are profound. A curative HBV product would create a multi‑billion‑dollar market, attract partnership interest, and set a precedent for gene‑editing therapeutics targeting other chronic viral infections. Investors will be watching enrollment metrics, safety signals, and early efficacy readouts closely, as success could validate the ARCUS platform and catalyze further funding for Precision’s pipeline. Conversely, setbacks would highlight the technical hurdles of in‑vivo editing, informing the broader industry’s risk assessment. Either way, the European expansion marks a pivotal milestone in the race to finally cure hepatitis B.